Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FFAR1 | O14842 | 4/20 | 0.50 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.47 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.46 |
| ▸ | FABP6 | P51161 | 1/20 | 0.45 |
| ▸ | MME | P08473 | 1/20 | 0.45 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.44 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.44 |
| ▸ | HTR2A | P28223 | 1/20 | 0.44 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.44 |
| ▸ | PLA2G4A | P47712 | 2/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5435694 | 0.86 | ALDH1A1 (0.49) | ALDH1A1SMN1; SMN2PTGDR2FABP6 | |
| SCHEMBL5431800 | 0.85 | ALDH1A1 (0.49) | ALDH1A1SMN1; SMN2PTGDR2FABP6CHRM1 | |
| SCHEMBL5442785 | 0.85 | CYP11B1 (0.54) | ALDH1A1SMN1; SMN2PTGDR2FABP6CHRM1 | |
| SCHEMBL5184702 | 0.85 | CHRM1 (0.49) | ALDH1A1SMN1; SMN2PTGDR2FABP6CHRM1 | |
| SCHEMBL16274898 | 0.83 | ALDH1A1 (0.55) | ALDH1A1SMN1; SMN2PTGDR2FABP6 | |
| SCHEMBL5433212 | 0.83 | ALDH1A1 (0.53) | ALDH1A1SMN1; SMN2PTGDR2FABP6 | |
| SCHEMBL5195770 | 0.82 | CYP11B1 (0.47) | ALDH1A1SMN1; SMN2PTGDR2FABP6CHRM1 | |
| SCHEMBL5439784 | 0.81 | FABP6 (0.47) | ALDH1A1SMN1; SMN2PTGDR2FABP6 | |
| SCHEMBL5195278 | 0.81 | FABP6 (0.47) | ALDH1A1SMN1; SMN2PTGDR2FABP6 | |
| SCHEMBL5438403 | 0.81 | MKNK1 (0.54) | ALDH1A1SMN1; SMN2PTGDR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130109652-A1 | NOVEL PYRIDINONE DERIVATIVES AND THEIR USE AS POSITIVE ALLOSTERIC MODULATORS OF MGLUR2-RECEPTORS | ADDEX PHARMACEUTICALS S.A. (CH) | 2013-05-02 | — | — | US | disclosed |
| US-8399493-B2 | Pyridinone derivatives and their use as positive allosteric modulators of mGluR2-receptors | Janssen Pharmaceuticals, Inc. (US) | 2013-03-19 | — | — | US | disclosed |
| US-20070213323-A1 | NOVEL PYRIDINONE DERIVATIVES AND THEIR USE AS POSITIVE ALLOSTERIC MODULATORS OF MGLUR2-RECEPTORS | Janssen Pharmaceuticals, Inc. | 2007-09-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070213323-A1 | NOVEL PYRIDINONE DERIVATIVES AND THEIR USE AS POSITIVE ALLOSTERIC MODULATORS OF MGLUR2-RECEPTORS | GRM2, GRM1, GRM3 | FFAR1 162/4885MAP4K4 2107/4885ALDH1A1 3403/4885 |
| US-20130109652-A1 | NOVEL PYRIDINONE DERIVATIVES AND THEIR USE AS POSITIVE ALLOSTERIC MODULATORS OF MGLUR2-RECEPTORS | GRM2, GRM1, GRIA2 | FFAR1 169/4885MAP4K4 1503/4885ALDH1A1 2717/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.